Table 1 Baseline Characteristics and Demographics of Patients
| Â | n (%) |
|---|---|
Gender | |
 Male | 53 (58.9) |
 Female | 37 (41.1) |
Race | |
 White | 70 (77.8) |
 Black | 16 (17.8) |
 Asian/Unknown | 4 (4.4) |
Histology | |
 Melanoma | 30 (33.3) |
 Gastrointestinal | 20 (22.2) |
 Lung, Head & Neck | 18 (20.0) |
 Breast | 11 (12.2) |
 Gynecological cancers | 3 (3.3) |
 Genitourinary cancers | 3 (3.3) |
 Others | 5 (5.6) |
Number of metastatic sites | |
 1 | 24 (26.7) |
 2 | 33 (36.7) |
 3+ | 33 (36.7) |
Sites of metastases | |
 Lymph node | 58 (64.4) |
 Liver | 40 (44.4) |
 Lung | 37 (41.1) |
 Bone | 24 (26.7) |
 Brain | 8 (8.9) |
ECOG PS | |
 0 | 34 (38.2) |
 1 | 55 (61.8) |
RMH Risk Group | |
 Good | 71 (80.7) |
 Poor | 17 (19.3) |
Checkpoint Indication | |
 Yes | 49 (54.4) |
 No | 41 (45.6) |
Treatment Regimen | |
 Anti-PD-L1 Monotherapy | 25 (27.8) |
 FDA-approved IO + Experimental IO | 46 (51.1) |
 Experimental IO Monotherapy | 19 (21.1) |
Number of prior systemic therapies in the metastatic setting | |
 0–1 | 28 (31.1) |
 2+ | 62 (68.9) |
Prior treatment with ICB | |
 Yes | 27 (30.0) |
 No | 63 (70.0) |